Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review

References

• Colston J, Atkins B. Bone and joint infection. Clin Med (Lond). 2018;18(2):150–154.
   PubMed Web of Science ®Google Scholar
• Boselli E, Allaouchiche B. [Diffusion in bone tissue of antibiotics]. Presse Med. 1999;28(40):2265–2276.
   PubMed Web of Science ®Google Scholar
• Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 2017;7(2):2.
   Web of Science ®Google Scholar
• Dijkmans AC, Zacarias NVO, Burggraaf J, et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics (Basel). 2017;6(4):4.
   Web of Science ®Google Scholar
• Dinh A, Salomon J, Bru JP, et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012;44(3):182–189.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis. 2008;27(6):439–443.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(5):497–499.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240–243.
   PubMed Web of Science ®Google Scholar
• Corvec S, Furustrand Tafin U, Betrisey B, et al. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013;57(3):1421–1427.
   PubMed Web of Science ®Google Scholar
• Mihailescu R, Furustrand Tafin U, Corvec S, et al. High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2014;58(5):2547–2553.
   PubMed Web of Science ®Google Scholar
• Oliva A, Furustrand Tafin U, Maiolo EM, et al. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2014;58(3):1284–1293.
   PubMed Web of Science ®Google Scholar
• Trautmann M, Meincke C, Vogt K, et al. Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics. Infection. 1992;20(6):350–354.
   PubMed Web of Science ®Google Scholar
• Antonello RM, Principe L, Maraolo AE, et al. Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics (Basel). 2020;9(8):8.
   Web of Science ®Google Scholar
• Hirakawa H, Kurabayashi K, Tanimoto K, et al. Oxygen limitation enhances the antimicrobial activity of fosfomycin in pseudomonas aeruginosa following overexpression of glpT which encodes glycerol-3-phosphate/fosfomycin symporter. Front Microbiol. 2018;9:1950.
   PubMed Web of Science ®Google Scholar
• Inouye S, Watanabe T, Tsuruoka T, et al. An increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditions. J Antimicrob Chemother. 1989;24(5):657–666.
   PubMed Web of Science ®Google Scholar
• Martin-Gutierrez G, Docobo-Perez F, Rodriguez-Beltran J, et al. Urinary tract conditions affect fosfomycin activity against escherichia coli strains harboring chromosomal mutations involved in fosfomycin uptake. Antimicrob Agents Chemother. 2017;62(1):1.
   Web of Science ®Google Scholar
• Sauermann R, Karch R, Langenberger H, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005;49(11):4448–4454.
   PubMed Web of Science ®Google Scholar
• Wittmann D. Chemotherapeutic principles of difficult-to-treat infections in surgery: II. Bone and joint infections. Infection. 1980;8(6):330–333.
   Web of Science ®Google Scholar
• Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86(2):156–167.
   PubMed Web of Science ®Google Scholar
• Poeppl W, Tobudic S, Lingscheid T, et al. Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(2):931–933.
   PubMed Web of Science ®Google Scholar
• Poeppl W, Lingscheid T, Bernitzky D, et al. Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats. Antimicrob Agents Chemother. 2014;58(9):5111–5116.
   PubMed Web of Science ®Google Scholar
• Schintler MV, Traunmuller F, Metzler J, et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother. 2009;64(3):574–578.
   PubMed Web of Science ®Google Scholar
• Rinaldi M, Cojutti PG, Zamparini E, et al. Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction. Antimicrob Agents Chemother. 2021;65(5):e02038-20.
   Web of Science ®Google Scholar
• Mazzei T, Cassetta MI, Fallani S, et al. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28(Suppl 1):S35–41.
   PubMedGoogle Scholar
• Corti N, Sennhauser FH, Stauffer UG, et al. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child. 2003;88(6):512–516.
   PubMed Web of Science ®Google Scholar
• Fitoussi F, Litzelmann E, Ilharreborde B, et al. Hematogenous osteomyelitis of the wrist in children. J Pediatr Orthop. 2007;27(7):810–813.
   PubMed Web of Science ®Google Scholar
• Gouyon JB, Duez JM, Portier H, et al. [Fosfomycin-cefotaxime combination in severe staphylococcal infections in newborn infants]. Presse Med. 1985;14(42):2135–2138.
   PubMed Web of Science ®Google Scholar
• Guggenbichler JP, Bonatti H, Rottensteiner F. [Resistance of staphylococci to intracellular killing by macrophages–a new pathophysiologic concept of acute hematogenous osteomyelitis in childhood and its therapeutic consequences]. Padiatr Padol. 1989;24(1):21–32.
   PubMedGoogle Scholar
• Hernandez Casado V. Fosfomycin in a traumatological department. Chemotherapy. 1977;23(Suppl 1):403–410.
   PubMedGoogle Scholar
• Lee WS, Chen YC, Chen HP, et al. Vertebral osteomyelitis caused by vancomycin-tolerant methicillin-resistant staphylococcus aureus bacteremia: experience with teicoplanin plus fosfomycin combination therapy. J Microbiol Immunol Infect. 2016;49(4):600–603.
   PubMedGoogle Scholar
• Meissner A, Haag R, Rahmanzadeh R. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection. 1989;17(3):146–151.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Yamaguchi T, Aoki K, et al. Imipenem plus fosfomycin as salvage therapy for vertebral osteomyelitis. Antimicrob Agents Chemother. 2020;65(1):1.
   Web of Science ®Google Scholar
• Portier H, Tremeaux JC, Chavanet P, et al. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother. 1984;14(Suppl B):277–284.
   PubMedGoogle Scholar
• Reinehr T, Burk G, Michel E, et al. Chronic osteomyelitis in childhood: is surgery always indicated? Infection. 2000;28(5):282–286.
   PubMed Web of Science ®Google Scholar
• Stengel D, Gorzer E, Schintler M, et al. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J Chemother. 2005;17(5):527–535.
   PubMed Web of Science ®Google Scholar
• Baron D, Desjars P, Touze M, et al. Clinical study on combined therapy with fosfomycin for staphylococcal lnfections. (Ed.^(Eds) (Service d’Urgence and Service de Reanimation Medicale H6tel-Oieu, Nantes, France, 1987)
   Google Scholar
• Stöckl B, Schmutzhard E. Antimikrobielle therapie der spondylodiszitis - überlegungen zur optimierung. Chemother J. 2005;14:11–15.
   Google Scholar
• Badelon O, Bingen E, Sauzeau C, et al. [Choice of first-line antibiotic therapy in the treatment of bone and joint infections in children]. Pathol Biol. 1988;36(5 Pt 2):746–749.
   PubMedGoogle Scholar
• Baron SA, Cassir N, Mekideche T, et al. Successful treatment and digestive decolonisation of a patient with osteitis caused by a carbapenemase-producing Klebsiella pneumoniae isolate harbouring both NDM-1 and OXA-48 enzymes. J Glob Antimicrob Resist. 2019;18:225–229.
   PubMed Web of Science ®Google Scholar
• Gillard J, Boutoille D, Varin S, et al. Suspected disk space infection with negative microbiological tests-report of eight cases and comparison with documented pyogenic discitis. Joint Bone Spine. 2005;72(2):156–162.
   PubMed Web of Science ®Google Scholar
• Luengo G, Lora-Tamayo J, Paredes D, et al. Daptomycin plus fosfomycin as salvage therapy in a difficult-to-treat total femoral replacement infection. J Bone Jt Infect. 2018;3(4):207–211.
   PubMedGoogle Scholar
• Narayanasamy S, Nation RL, Mahony AA, et al. Cure of limb-threatening XDR pseudomonas aeruginosa infection: combining genome sequencing, therapeutic drug level monitoring, and surgical debridement .Open Forum Infect Dis. 2020;8(1):ofaa572.
   PubMed Web of Science ®Google Scholar
• Agency EM Fosfomycin-containing medicinal products. (Ed.^(Eds) (2020)
   Google Scholar
• Agency EM Recommendations to restrict use of fosfomycin antibiotics (Ed.^(Eds) (2020)
   Google Scholar
• Gutierrez K. Bone and joint infections in children. Pediatr Clin North Am. 2005;52(3):779–794.
   PubMed Web of Science ®Google Scholar
• Putensen C, Ellger B, Sakka SG, et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019;47(5):827–836.
   PubMed Web of Science ®Google Scholar
• Renz N, Trebse R, Akgun D, et al. Enterococcal periprosthetic joint infection: clinical and microbiological findings from an 8-year retrospective cohort study. BMC Infect Dis. 2019;19(1):1083.
   PubMed Web of Science ®Google Scholar
• Rieg S, Ernst A, Peyerl-Hoffmann G, et al. Combination therapy with rifampicin or fosfomycin in patients with Staphylococcus aureus bloodstream infection at high risk for complications or relapse: results of a large prospective observational cohort. J Antimicrob Chemother. 2020;75(8):2282–2290.
   PubMed Web of Science ®Google Scholar
• Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: current concepts and outlook. EFORT Open Rev. 2019;4(7):482–494.
   PubMed Web of Science ®Google Scholar
• Li C, Renz N, Trampuz A, et al. Twenty common errors in the diagnosis and treatment of periprosthetic joint infection. Int Orthop. 2019;44(1):3–14.
   PubMed Web of Science ®Google Scholar
• Steinmetz S, Wernly D, Moerenhout K, et al. Infection after fracture fixation. EFORT Open Rev. 2019;4(7):468–475.
   PubMed Web of Science ®Google Scholar
• Urish KL, Cassat JE. Staphylococcus aureus osteomyelitis: bone, bugs, and surgery. Infect Immun. 2020;88(7):7.
   Web of Science ®Google Scholar
• Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369–379.
   PubMed Web of Science ®Google Scholar
• Ballestero-Tellez M, Docobo-Perez F, Rodriguez-Martinez JM, et al. Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in enterobacteriaceae. Clin Microbiol Infect. 2017;23(5):325–331.
   PubMed Web of Science ®Google Scholar
• Walsh CC, McIntosh MP, Peleg AY, et al. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 2015;70(11):3042–3050.
   PubMed Web of Science ®Google Scholar
• Grabein B, Graninger W, Rodriguez Bano J, et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23(6):363–372.
   PubMed Web of Science ®Google Scholar
• Bendtsen MAF, Bue M, Hanberg P, et al. Flucloxacillin bone and soft tissue concentrations assessed by microdialysis in pigs after intravenous and oral administration. Bone Joint Res. 2021;10(1):60–67.
   PubMed Web of Science ®Google Scholar
• Zimmerli W. Bone and joint infections: from microbiology to diagnostics and treatment. Wiley-Blackwell: USA;2015.
   Google Scholar
• Bodmann KFHS, Kluge S, Lindau S, et al. Intravenous (i.v.) fosfomycin for treatment of severely infected patients (FORTRESS): first insights from a European, multicentre, non-interventional and prospective clinical study. Presented at 29th ECCMID, Amsterdam, Netherlands, 2019
   Google Scholar
• Karbysheva S, Margaryan D, Trampuz A Efficacy and safety of intravenous fosfomycin in periprosthetic joint infection: preliminary results from the PROOF study -a prospective multicenter study. Presented at 29th ECCMID, Amsterdam, Netherlands, 2019.
   Google Scholar
• Vossen MG, Gattringer R, Thalhammer F, et al. Calculated parenteral initial treatment of bacterial infections: bone and joint infections. GMS Infect Dis. 2020;8: Doc10.
   PubMedGoogle Scholar